ArticleDiabetes, obesity & metabolism2019
When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic control.
Article in Diabetes, obesity & metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Effects of insulin regimens for type 2 diabetes mellitus: a systematic review and network meta-analysis.Diabetologia · 2026Pooled it
- Fasting Glucose of 6.1 mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial.Journal of diabetes research · 2021Trial
- Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: Results of a multicentre, open-label, randomized controlled trial (BEYOND VII).Diabetes, obesity & metabolism · 2020Trial
- Review
- Crosstalk Between Oxidative Stress, Protein Glycation, and Extracellular Matrix Remodeling in the Skin of Rats with Type 1 Diabetes: Does Insulin Administration Improve Skin Homeostasis?Antioxidants (Basel, Switzerland) · 2026Article
- Overbasalization and glycemic control: longitudinal analysis in people with type 2 diabetes in Peru.Journal of diabetes and metabolic disorders · 2025Article
- Definition of Overbasalization.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults With Type 2 Diabetes in the Philippines: Results from a Prospective, Non-interventional, Real-World Study.Journal of the ASEAN Federation of Endocrine Societies · 2024Article
- Quantifying and Characterizing the Presence of Insulin Overbasalization in a Family Medicine Practice.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- A Conversation on an Effective, Straightforward, Quantitative Approach to the Outpatient Use of Insulin.Diabetes spectrum : a publication of the American Diabetes Association · 2022Article
- Clinical Overbasalization Revisited.Clinical diabetes : a publication of the American Diabetes Association · 2022Article
- Practicable Measurement and Identification of Overbasalization.Clinical diabetes : a publication of the American Diabetes Association · 2022Article
- The Clinical Definition of Overbasalization.Clinical diabetes : a publication of the American Diabetes Association · 2021Article
- Prevalence of and Characteristics Associated With Overbasalization Among Patients With Type 2 Diabetes Using Basal Insulin: A Cross-Sectional Study.Clinical diabetes : a publication of the American Diabetes Association · 2021Article
- Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.Diabetes, obesity & metabolism · 2020Review
- Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin.Clinical diabetes : a publication of the American Diabetes Association · 2020Review
- Use of Premixed Insulin, Metformin, and a Glucagon-Like Peptide 1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes.Diabetes spectrum : a publication of the American Diabetes Association · 2020Article
- Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.Advances in therapy · 2019Article
- When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units/mL and glycaemic control.Diabetes, obesity & metabolism · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
aimsA post-hoc analysis to assess the impact in people with type 2 diabetes, of increasing doses of basal insulin on glycaemic measures, body weight and hypoglycaemia. RESEARCH DESIGN AND
methodsWe included data from prospective, randomized controlled treat-to-target trials of ≥24 weeks' duration in people with type 2 diabetes, uncontrolled on metformin and sulphonylureas, and treated with insulin glargine 100 units/mL (U100), who had at least six fasting plasma glucose (FPG) measurements. The impact of insulin dose on glycated haemoglobin (HbA1c) values, FPG, hypoglycaemia incidence (<3.9 mmol/L [70 mg/dL]), and body weight was analysed. A total of 458 participants from three eligible trials were included.
resultsThe observed relationship between higher basal insulin doses and glycaemic control was non-linear, with increasing insulin dose leading to smaller reductions in FPG and HbA1c for doses >0.3 IU/kg/d, with a plateauing effect at 0.5 IU/kg/d. Total daily dose of insulin >0.5 IU/kg/d resulted in greater weight gain, but without higher rates of hypoglycaemia, compared with insulin doses ≤0.5 IU/kg/d.
conclusionsThis analysis indicates that basal insulin doses >0.5 IU/kg/d have diminishing additional impact on improving glycaemic measures, with the disadvantage of additional weight gain. Clinicians should consider anti-hyperglycaemic treatment intensification at doses approaching 0.5 IU/kg/d.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.